NVS
Novartis AG$146.42
+1.02%LiveJun 08, 2026
Market cap
$279.38B
52w range
112.34 – 170.46
P / E
—
EPS
—
Volume
2.59M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Novartis AG’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $141.00 (-3.70%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.84% | -0.03% | +0.27% | -10.06% | +11.76% | +6.20% | +24.06% | +53.30% | +67.78% | +117.37% | +830.83% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$146.05
Bid
$145.00
1 sh
Ask
$146.55
30 sh
Spread
$1.550
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Communication Services+0.40%
- Financial Services+0.18%
- Energy+0.01%
- Technology-0.07%
- Consumer Cyclical-0.13%
- Consumer Defensive-0.45%
- Healthcare-0.50%
- Industrials-0.73%
- Basic Materials-1.36%
- Utilities-1.53%
- Real Estate-1.58%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.87%
- Solar-6.96%
- REIT - Healthcare Facilities-3.27%
- Construction Materials-3.10%
- Copper-3.02%
- Biotechnology-2.86%
- Medical - Healthcare Information Services-2.58%
- Financial - Mortgages-2.51%
- Software - Infrastructure-2.48%
- Security & Protection Services-2.31%
- Electrical Equipment & Parts-2.27%
- REIT - Specialty-2.22%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$141.00
-3.70% upside
Low
$112.00
Median
$141.00
High
$170.00
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026globenewswire.com·Jun 08, 2026
- Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026globenewswire.com·Jun 08, 2026
- Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsglobenewswire.com·Jun 04, 2026
- Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsglobenewswire.com·Jun 04, 2026
- Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsglobenewswire.com·Jun 03, 2026
- Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsglobenewswire.com·Jun 03, 2026
- Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilitiesglobenewswire.com·May 07, 2026
Peers
No peer list available for NVS.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|